Treatment of MDA-MB-231 human breast cancer cells with cytotoxic agent doxorubicin (10-9 M; positive control) or with of the GnRH-II antagonist (10-9 and 10-7 M) for 48 h resulted in increased caspase-3 activity (Figure 2b). This evidence concerns the gene GNRH2 and breast cancer.